ArticleAntimicrobial agents and chemotherapy2012
Characterization of CIA-1, an Ambler class A extended-spectrum β-lactamase from Chryseobacterium indologenes.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Active site loops of membrane-anchored metallo-β-lactamases from environmental bacteria determine cephalosporinase activity.Antimicrobial agents and chemotherapy · 2025Article
- Identification and characterization of CIM-1, a carbapenemase that adds to the family of resistance factors against last resort antibiotics.Communications biology · 2024Article
- Novel Antibiotic Resistance Genes Identified by Functional Gene Library Screening inInternational journal of molecular sciences · 2023Article
- Phenotypical Detection of β-Lactamases in a Multidrug-Resistant and Extensively Drug-ResistantMicrobiology insights · 2023Article
- Characteristics ofAccess microbiology · 2023Article
- RAA Enzyme Is a New Family of Class A Extended-Spectrum β-Lactamase from Riemerella anatipestifer Strain RCAD0122.Antimicrobial agents and chemotherapy · 2022Article
- Whole genome sequencing of the multidrug-resistantFrontiers in medicine · 2022Article
- Clinical and molecular characteristics ofAnnals of translational medicine · 2021Article
- Article
- First Isolation and Characterization ofPathogens (Basel, Switzerland) · 2020Article
- Rare case of meningitis due to an emerging pathogenSAGE open medical case reports · 2020Article
- Nasal Resistome Development in Infants With Cystic Fibrosis in the First Year of Life.Frontiers in microbiology · 2019Article
- Article
- Whole genome sequencing for deciphering the resistome of Chryseobacterium indologenes, an emerging multidrug-resistant bacterium isolated from a cystic fibrosis patient in Marseille, France.New microbes and new infections · 2016Article
- A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.Clinical microbiology reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An Ambler class A β-lactamase gene, bla(CIA-1), was cloned from the reference strain Chryseobacterium indologenes ATCC 29897 and expressed in Escherichia coli BL21. The bla(CIA-1) gene encodes a novel extended-spectrum β-lactamase (ESBL) that shared 68% and 60% identities with the CGA-1 and CME-1 β-lactamases, respectively. bla(CIA-1)-like genes were detected from clinical isolates. In addition to the metallo-β-lactamase IND of Ambler class B, C. indologenes has a class A ESBL gene, bla(CIA-1), located on the chromosome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.